MedTrace Logo

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

NCT03699618 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2020-02-19

No results posted yet for this study

Summary

This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).

Conditions

  • Submacular Hemorrhage
  • Wet Macular Degeneration
  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Anti-VEGF

Standard of care treatment with anti-VEGF only

OTHER

Hemorrhage displacement + Anti-VEGF

Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections

Sponsors & Collaborators

Principal Investigators

  • Peter Campochiaro, MD · Wilmer Eye Institute

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2020-01-06
Completion
2020-01-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03699618 on ClinicalTrials.gov